BlueWillow Biologics’ NanoVax® technology (W805EC oil-in-water adjuvant) is transforming the prevention and treatment landscape for infectious disease and pandemic preparedness. Our clinical-stage intranasal adjuvant and antigen delivery platform is the most advanced in development.
The NanoVax® platform is compatible with a broad array of viral, bacterial, and food antigens. Safety and immunogenicity of the W805EC adjuvant has been established in successful human clinical trials. The adjuvant elicits a balanced mucosal, systemic and Th1 dominant cellular immune response ideal for robust protection against both symptomatic disease and carriage/transmission.